Cerenome Projects $1.55 Million in Third Quarter Gross Billings for CNSide®
Cerenome anticipates $1.55 million in gross billings for its CNSide® product in the third quarter, according to The Manila Times.
Billings, MT, September 30, 2026 —
Cerenome has projected $1.55 million in gross billings for its CNSide® product during the third quarter. This forecast was reported by The Manila Times.
The company’s anticipation of this revenue figure pertains specifically to its CNSide® product line. Details regarding the specific factors contributing to this projection, such as market demand, sales performance, or expansion efforts, were not provided in the initial report. The timeframe for these anticipated billings is the third quarter of the current fiscal year.
No further information was immediately available regarding the company’s performance in previous quarters, nor were specific growth targets or comparisons made. The source of the information, The Manila Times, provided the figure without additional commentary on its implications for the company or the broader market.
The contractor’s name, if applicable to the CNSide® product’s development or distribution, was not provided. Similarly, any information regarding permits, inspection outcomes, code violations, or fine amounts associated with Cerenome or its products was absent from the report.
The financial figure of $1.55 million represents anticipated gross billings. This figure is a projection and not a confirmed revenue amount. The nature of the CNSide® product and its specific applications within the market were not detailed in the summary provided.
Story summarized from the original created by Google News on news.google.com, see more information here.
